Supernus Pharmaceuticals Inc (SUPN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9787
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc (SUPN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 10
Licensing Agreements 11
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 11
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 12
Especificos Stendhal Enters into Licenisng Agreement with Supernus Pharma 13
Equity Offering 14
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 14
Supernus Pharma Completes IPO For USD52.3 Million 16
Debt Offering 18
Supernus Pharma Raises USD402.5 Million in Private Placement of Notes Due 2023 18
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 19
Acquisition 21
Supernus Pharma to Acquire Biscayne Neurotherapeutics 21
Supernus Pharmaceuticals Inc – Key Competitors 23
Supernus Pharmaceuticals Inc – Key Employees 24
Supernus Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 06, 2018: Supernus announces third quarter 2018 financial results and record quarterly revenue 26
Aug 07, 2018: Supernus announces second quarter 2018 financial results and record quarterly revenue 28
May 08, 2018: Supernus Reports First Quarter 2018 Financial Results 30
Feb 27, 2018: Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance 32
Nov 06, 2017: Supernus Announces Third Quarter 2017 Financial Results 34
Aug 02, 2017: Supernus Announces Record Second Quarter 2017 Financial Results 36
May 09, 2017: Supernus Announces First Quarter 2017 Financial Results 38
Feb 28, 2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 42
Jun 27, 2018: Supernus Pharmaceuticals Names Dr. Carrolee Barlow As Board Director 42
Clinical Trials 43
Sep 18, 2017: Supernus Provides Update on SPN-810 Phase III Clinical Trials 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 10
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 11
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 12
Especificos Stendhal Enters into Licenisng Agreement with Supernus Pharma 13
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 14
Supernus Pharma Completes IPO For USD52.3 Million 16
Supernus Pharma Raises USD402.5 Million in Private Placement of Notes Due 2023 18
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 19
Supernus Pharma to Acquire Biscayne Neurotherapeutics 21
Supernus Pharmaceuticals Inc, Key Competitors 23
Supernus Pharmaceuticals Inc, Key Employees 24
Supernus Pharmaceuticals Inc, Subsidiaries 25

List of Figures
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Supernus Pharmaceuticals Inc (SUPN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Inter Pipeline Ltd (IPL):企業の財務・戦略的SWOT分析
    Inter Pipeline Ltd (IPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BioMarin Pharmaceutical Inc.:企業の戦略・SWOT・財務情報
    BioMarin Pharmaceutical Inc. - Strategy, SWOT and Corporate Finance Report Summary BioMarin Pharmaceutical Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Hydro-Quebec:電力:M&Aディール及び事業提携情報
    Summary Hydro-Quebec is a government-owned energy utility that generates, transmits and distributes electricity. The company specializes in renewable energy generation, using hydro sources and supports the development of electricity using other technologies such as wind energy and biomass. It genera …
  • Saipem SpA (SPM):石油・ガス:M&Aディール及び事業提携情報
    Summary Saipem SpA (Saipem) is an engineering, procurement, construction (EPC) contractor. It provides integrated basic design, Pre-front end engineering design (FEED), FEED and detailed EPC and project management services for complex offshore and onshore projects in the oil and gas industry. The co …
  • Hostess Brands Inc (TWNK):企業の財務・戦略的SWOT分析
    Hostess Brands Inc (TWNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • The Hain Celestial Group Inc (HAIN):企業の財務・戦略的SWOT分析
    The Hain Celestial Group Inc (HAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Scatec Solar ASA (SSO):電力:M&Aディール及び事業提携情報
    Summary Scatec Solar ASA (Scatec Solar) is an integrated independent producer of solar power that develops, builds, owns and operates solar power plants. It conducts project origination and development, project financing, design and engineering, procurement and construction management, operation and …
  • Quaker Chemical Corp (KWR):企業の財務・戦略的SWOT分析
    Quaker Chemical Corp (KWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • CornerStone Research & Development Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CornerStone Research & Development Inc (Capstone Nutrition), doing business as Capstone Nutrition Inc is a developer and manufacturer of nutrition products. The company offers development, production and packaging of capsule, tablet, and powder products. It offers product ideation, formulati …
  • Trinidad Drilling Ltd (TDG):企業の財務・戦略的SWOT分析
    Summary Trinidad Drilling Ltd (Trinidad Drilling) is an oil and gas company that offers drilling services. The company’s services include land and barge drilling, coring and presetting, well servicing, rig design and management, rig fleet management, and technical support services. Its in-house manu …
  • OncoSil Medical Ltd (OSL):企業の財務・戦略的SWOT分析
    Summary OncoSil Medical Ltd (OncoSil), is a medical device company that develops and commercializes products for the treatment of pancreatic and liver cancer. The company’s lead product includes oncosil, a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous …
  • ISMT Limited:企業の戦略・SWOT・財務情報
    ISMT Limited - Strategy, SWOT and Corporate Finance Report Summary ISMT Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Billabong International Limited (BBG):企業の財務・戦略的SWOT分析
    Billabong International Limited (BBG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • ESAB Holdings Ltd:企業の戦略・SWOT・財務情報
    ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Global Investment House KPSC:企業の戦略的SWOT分析
    Global Investment House KPSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • The Menarini Group:企業の戦略・SWOT・財務情報
    The Menarini Group - Strategy, SWOT and Corporate Finance Report Summary The Menarini Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Ardelyx Inc (ARDX):企業の財務・戦略的SWOT分析
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in …
  • Rebiotix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rebiotix Inc (Rebiotix), formerly MikrobEX Inc is a clinical stage biotechnology company that develops treatments for debilitating diseases. The company targets various disease conditions using drugs based on its microbiota restoration therapy platform. It lead product candidate RBX2660 is u …
  • Denny’s Corporation:戦略・SWOT・企業財務分析
    Denny's Corporation - Strategy, SWOT and Corporate Finance Report Summary Denny's Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Tata Communications Limited:企業の戦略・SWOT・財務情報
    Tata Communications Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Communications Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆